BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Suven Life Sciences Ltd Presenting the Pre-Clinical Data of Their NCEs at Society For Neuroscience (SFN-2011) Annual Meeting at Washington DC, USA


11/14/2011 9:50:57 AM

HYDERABAD, INDIA (Nov 14, 2011) – Suven Life Sciences is presenting several data presentations from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2011 from 13 th to 16th of Nov held at Washington DC, USA. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro- Scientists from all over the world covering all the major Pharma, biotech and research institutes will be participating Suven’s nine (9) data presentations covers the early-stage compounds from Histamine-3 receptor antagonist, Nicotinic acetylcholine alpha-4-beta-2 receptor agonist and antagonist, Serotonin 5-HT4 receptor agonist in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain. These data presentation highlights Suven’s continued commitment to exploring new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $30 billion.

During SFN-2011 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global pharma majors regarding their clinical candidate SUVN-502.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders, Sleep, Neurodegeneration and Obesity through CNS targets.

For more information on Suven, please visit our Web site at http://www.suven.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES